InsiderTrades.com logo

PBLS Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $10,723,528.30
Insider Selling (Last 12 Months): $0.00

Parabilis Medicines Insider Trading History Chart

This chart shows the insider buying and selling history at Parabilis Medicines by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Parabilis Medicines Share Price & Price History

Current Price: $36.88
Price Change: +0.30 (1.20%)
As of 09/11/2026 04:00 PM ET

This chart shows the closing price history over time for PBLS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Parabilis Medicines Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/15/2026Alan SebulskyDirectorBuy9,065$26.49$240,131.8530,000View SEC Filing Icon  
6/12/2026Alan SebulskyDirectorBuy8,435$27.67$233,396.4520,935View SEC Filing Icon  
6/11/2026Alan SebulskyDirectorBuy12,500$20.00$250,000.0012,500View SEC Filing Icon  
6/11/2026Guy LevyMajor ShareholderBuy500,000$20.00$10,000,000.001,027,000View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Parabilis Medicines (NASDAQ:PBLS)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PBLS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Parabilis Medicines Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
9/9/2026WINTON GROUP Ltd34,900$0.96M0.0%N/A0.028%Search for SEC Filing on Google Icon
9/9/2026Squarepoint Ops LLC48,484$1.33M0.0%N/A0.039%Search for SEC Filing on Google Icon
8/23/2026Frazier Life Sciences Management L.P.1,920,805$52.57M1.1%N/A1.626%Search for SEC Filing on Google Icon
8/20/2026ICONIQ Capital LLC350,000$9.58M0.3%N/A0.296%Search for SEC Filing on Google Icon
8/20/2026Alyeska Investment Group L.P.10,000$0.27M0.0%N/A0.008%Search for SEC Filing on Google Icon
8/19/2026Regeneron Pharmaceuticals Inc.4,166,666$114.04M64.4%N/A3.527%Search for SEC Filing on Google Icon
8/18/2026venBio Partners LLC5,266,697$144.15M0.0%N/A4.458%Search for SEC Filing on Google Icon
8/18/2026General Catalyst Group Management LLC1,600,937$43.82M23.2%N/A1.355%Search for SEC Filing on Google Icon
8/15/2026Jupiter Topco LLC2,296,547$62.71M0.0%N/A1.944%Search for SEC Filing on Google Icon
8/15/2026ARCH Venture Management LLC6,412,780$175.52M0.0%N/A5.428%Search for SEC Filing on Google Icon
8/13/2026ICONIQ Capital LLC350,000$9.58M0.3%N/A0.296%Search for SEC Filing on Google Icon
8/7/2026Alphabet Inc.4,919,498$134.65M0.1%N/A4.164%Search for SEC Filing on Google Icon
8/7/2026Mitsubishi UFJ Asset Management Co. Ltd.19,200$0.53M0.0%N/A0.016%Search for SEC Filing on Google Icon
8/7/2026Persistent Asset Partners Ltd4,130$0.11M0.0%N/A0.003%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Parabilis Medicines logo
Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.
Read More on Parabilis Medicines

Today's Range

Now: $36.88
Low: $36.44
High: $37.74

50 Day Range

MA: $35.13
Low: $27.31
High: $41.32

52 Week Range

Now: $36.88
Low: $24.51
High: $41.49

Volume

364,813 shs

Average Volume

405,112 shs

Market Capitalization

$4.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Parabilis Medicines?

Parabilis Medicines' top insider investors include:
  1. Guy Levy (Major Shareholder)
  2. Alan Sebulsky (Director)
Learn More about top insider investors at Parabilis Medicines.

Who are the major institutional investors of Parabilis Medicines?

Parabilis Medicines' top institutional investors include:
  1. ARCH Venture Management LLC — 5.43%
  2. venBio Partners LLC — 4.46%
  3. Alphabet Inc. — 4.16%
  4. Regeneron Pharmaceuticals Inc. — 3.53%
  5. Jupiter Topco LLC — 1.94%
  6. Frazier Life Sciences Management L.P. — 1.63%
Learn More about top institutional investors of Parabilis Medicines stock.

Which major investors are buying Parabilis Medicines stock?

During the last quarter, PBLS stock was bought by institutional investors including:
  1. ARCH Venture Management LLC
  2. venBio Partners LLC
  3. Alphabet Inc.
  4. Regeneron Pharmaceuticals Inc.
  5. Jupiter Topco LLC
  6. Frazier Life Sciences Management L.P.
  7. General Catalyst Group Management LLC
  8. ICONIQ Capital LLC
During the previous year, these company insiders have bought Parabilis Medicines stock:
  1. Guy Levy (Major Shareholder)
  2. Alan Sebulsky (Director)
Learn More investors buying Parabilis Medicines stock.

Parabilis Medicines Active Insiders

Alan Sebulsky
Director
3 recent trades